Physician profile
Michael W Quartuccio
NPI 1093030553
$129,646.18
in general payments reported to CMS, 2019-2025
12 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $1,292 · 2022: $25K · 2023: $25K · 2024: $25K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $2,790 · Travel and Lodging: $2,296 · Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,272.19 |
| Consulting Fee | $2,790.00 |
| Travel and Lodging | $2,295.85 |
| Food and Beverage | $2,198.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $123,084.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Cequr Corporation | $4,796.66 | 2024-2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $930.00 | 2020 | |
| Lilly USA, LLC | $144.66 | 2022-2024 | Mounjaro |
| Horizon Therapeutics Plc | $123.94 | 2020 | |
| Tandem Diabetes Care, INC. | $116.89 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Baxter Healthcare | $103.27 | 2024 | Tisseel |
| Abbott Laboratories | $99.98 | 2019 | |
| Radius Health, INC. | $98.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.67 | 2020 | |
| Sanofi-Aventis U.S. LLC | $57.78 | 2019 | |
| Sequel Med Tech, LLC | $14.47 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Quartuccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.